Weekly First-Line Abraxane Yields Benefit

Article

Weekly first-linetherapy with nab-paclitaxel (Abraxane)was well tolerated and showed strongclinical responses in taxane-refractorylocally advanced or metastatic breast cancer,report researchers from the InternationalOncology Network.

DALLAS–Weekly first-linetherapy with nab-paclitaxel (Abraxane)was well tolerated and showed strongclinical responses in taxane-refractorylocally advanced or metastatic breast cancer,report researchers from the InternationalOncology Network (abstract6073). Lead investigator Barry C.Mirtsching, MD, discussed the phase IIopen-label nonrandomized study.

Patients received nab-paclitaxel at 125mg/m2 on days 1, 8, and 15 of a 28-daycycle. HER2-positive patients wereallowed to receive trastuzumab(Herceptin), and underwent cardiacmonitoring at regular intervals. A medianof 4 cycles of chemotherapy (range 1to 15) were administered, and dose wasreduced in about one-fourth of patients,due to toxicity. At analysis, 67 patientshad been treated, and 35 (1 male) wereevaluable for response; 25 were HER2-negative, 9 were HER2-positive, andHER2 status was unavailable for 1 patient.The primary endpoint was ORR.

Good Efficacy, Safety

The CR/PR was 74.3% (26 patients).An additional 8 patients had stable disease.Median time to objective responsewas 3.5 months. Median TTP was 12.6months, and overall survival at 14months (median OS not reached at analysis)was 71.2%.

The CR/PR was 74.3% (26 patients).An additional 8 patients had stable disease.Median time to objective responsewas 3.5 months. Median TTP was 12.6months, and overall survival at 14months (median OS not reached at analysis)was 71.2%.

Dr. Mirtsching and colleagues reportedthat the most common grade 3 toxicitieswere neutropenia (10.4% of patients);neuropathy (6.0%); fatigue(4.5%); and muscle weakness, joint pain,dyspnea, and thrombosis (all at 3%).Grade 4 toxicities were supraventriculartachycardia and vascular disorder, eachoccurring in 1.5% of evaluable patients.

Though the data are preliminary, theinvestigators concluded that they demonstrate"significant efficacy of weeklyAbraxane in the first-line treatment ofmetastatic breast cancer, and a favorablesafety profile."

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content